- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Journal of Nuclear Medicine, 65, 1, S. 79-84
- Ereignis
-
Veröffentlichung
- (wo)
-
Augsburg
- (wer)
-
Universität Augsburg
- (wann)
-
2024
- Ereignis
-
Veröffentlichung
- (wer)
-
Society of Nuclear Medicine
- (wann)
-
2024
- Urheber
-
Steinhelfer, Lisa
Lunger, Lukas
Cala, Lisena
Pfob, Christian H.
Lapa, Constantin Frederik Victor
Hartrampf, Philipp E.
Buck, Andreas K.
Schäfer, Hannah
Schmaderer, Christoph
Tauber, Robert
Brosch-Lenz, Julia
Haller, Bernhard
Meissner, Valentin H.
Knorr, Karina
Weber, Wolfgang A.
Eiber, Matthias
- DOI
-
10.2967/jnumed.123.265986
- URN
-
urn:nbn:de:bvb:384-opus4-1118098
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:03 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Steinhelfer, Lisa
- Lunger, Lukas
- Cala, Lisena
- Pfob, Christian H.
- Lapa, Constantin Frederik Victor
- Hartrampf, Philipp E.
- Buck, Andreas K.
- Schäfer, Hannah
- Schmaderer, Christoph
- Tauber, Robert
- Brosch-Lenz, Julia
- Haller, Bernhard
- Meissner, Valentin H.
- Knorr, Karina
- Weber, Wolfgang A.
- Eiber, Matthias
- Universität Augsburg
- Society of Nuclear Medicine
Entstanden
- 2024
Ähnliche Objekte (12)
Molekulare Bildgebung der Proliferation in vivo mit Positronen-Emissions-Tomographie
![Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy](/assets/placeholder/searchResultMediaUnknown.png)
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T
Development of discordant hypermetabolic prostate cancer lesions in the course of [177Lu]PSMA radioligand therapy and their possible influence on patient outcome
Einfluss der PSMA-Expression auf die Docetaxel-Sensitivität sowie systemischer Medikamente auf die Expression von PSMA, CXCR4 und SSTR2
Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up
Lenvatinib : Multikinaseinhibitoren - die erste effektive Therapie für das Radiobiod-refraktäre differenzierte Schilddrüsenkarzinom
Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients
Molekulare Bildgebung der Proliferation in vivo mit Positronen-Emissions-Tomographie
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T
Development of discordant hypermetabolic prostate cancer lesions in the course of [177Lu]PSMA radioligand therapy and their possible influence on patient outcome
Einfluss der PSMA-Expression auf die Docetaxel-Sensitivität sowie systemischer Medikamente auf die Expression von PSMA, CXCR4 und SSTR2
Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up
Lenvatinib : Multikinaseinhibitoren - die erste effektive Therapie für das Radiobiod-refraktäre differenzierte Schilddrüsenkarzinom
Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients
Molekulare Bildgebung der Proliferation in vivo mit Positronen-Emissions-Tomographie
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T
Development of discordant hypermetabolic prostate cancer lesions in the course of [177Lu]PSMA radioligand therapy and their possible influence on patient outcome
Einfluss der PSMA-Expression auf die Docetaxel-Sensitivität sowie systemischer Medikamente auf die Expression von PSMA, CXCR4 und SSTR2
Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up
Lenvatinib : Multikinaseinhibitoren - die erste effektive Therapie für das Radiobiod-refraktäre differenzierte Schilddrüsenkarzinom
Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer